Literature DB >> 8978293

Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.

R Zambello1, M Facco, L Trentin, R Sancetta, C Tassinari, A Perin, A Milani, G Pizzolo, F Rodeghiero, C Agostini, R Meazza, S Ferrini, G Semenzato.   

Abstract

The recently cloned cytokine interleukin-15 (IL-15) shares several functional activities with IL-2 in different cell systems. Although IL-15 does not show sequence homology with IL-2, it uses components of the IL-2 receptor (IL-2R) for binding and signal transduction, namely, p75 (beta) and the p64 (gamma) chains of IL-2R. To evaluate whether IL-15 is involved in the activation of granular lymphocytes (GL) in patients with lymphoproliferative disease of granular lymphocytes (LDGL), we evaluated the ability of IL-15 to stimulate GL proliferation, cytotoxic function, and the role of IL-2R beta and gamma molecules on relevant cells. Our results show that IL-15 stimulates cell proliferation and cytotoxic activity of GL in LDGL patients. Reverse-transcriptase polymerase chain reaction (RT-PCR) and phenotypic analyses using the anti-IL-2R gamma-chain-specific TUGh4 monoclonal antibody (MoAb) indicate that both CD3+ and CD3- GL express the p64 IL-2R, a result previously unknown. IL-15 activity was inhibited by antibodies against p75 and p64 IL-2R chains, while no inhibitory effects are detectable with anti-p55 IL-2R antibody. The association of anti-p75 and anti-p64 IL-2R MoAbs resulted in a nearly complete (95%) inhibition of IL-15-induced GL proliferation. Using RT-PCR analysis, we demonstrated that highly purified CD3+ and CD3- GL did not express mRNA for IL-15 or IL-2. By contrast, a clear-cut IL-15 mRNA signal was detected by RT-PCR in patients' peripheral blood mononuclear cells, with monocytes likely accounting for the source of IL-15 in LDGL patients. However, even in concentrated supernatants from enriched monocyte populations, we could not demonstrate the presence of IL-15 protein. Using anti-IL-15 specific MoAbs, a membrane-bound form of this cytokine was demonstrated both on CD3+ and CD3- LDGL cells. By RT-PCR analysis, purified GL from these patients were found to express the message for IL-15 receptor alpha chain. Taken together, these results indicate that both CD3+ and CD3- GL are stimulated by IL-15 and that this cytokine mediates its activity through the beta and gamma chains of the IL-2R, providing further suggestions for the interpretation of the mechanisms that lead to cell expansion in patients with LDGL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978293

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Enhanced neutrophil response in chronic obstructive pulmonary disease.

Authors:  A Noguera; S Batle; C Miralles; J Iglesias; X Busquets; W MacNee; A G Agustí
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

2.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

3.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

4.  Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

Authors:  Joerg U Schmohl; Martin Felices; Elizabeth Taras; Jeff S Miller; Daniel A Vallera
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

Review 5.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

6.  Network model of survival signaling in large granular lymphocyte leukemia.

Authors:  Ranran Zhang; Mithun Vinod Shah; Jun Yang; Susan B Nyland; Xin Liu; Jong K Yun; Réka Albert; Thomas P Loughran
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

7.  Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.

Authors:  Anjali Mishra; Shujun Liu; Gregory H Sams; Douglas P Curphey; Ramasamy Santhanam; Laura J Rush; Deanna Schaefer; Lauren G Falkenberg; Laura Sullivan; Laura Jaroncyk; Xiaojuan Yang; Harold Fisk; Lai-Chu Wu; Christopher Hickey; Jason C Chandler; Yue-Zhong Wu; Nyla A Heerema; Kenneth K Chan; Danilo Perrotti; Jianying Zhang; Pierluigi Porcu; Frederick K Racke; Ramiro Garzon; Robert J Lee; Guido Marcucci; Michael A Caligiuri
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

8.  Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture.

Authors:  Sunwoong S Choi; Vaninder S Chhabra; Quoc H Nguyen; Bonnie J Ank; E Richard Stiehm; Robert L Roberts
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo.

Authors:  Cristina Bergamaschi; Rashmi Jalah; Viraj Kulkarni; Margherita Rosati; Gen-Mu Zhang; Candido Alicea; Andrei S Zolotukhin; Barbara K Felber; George N Pavlakis
Journal:  J Immunol       Date:  2009-09-01       Impact factor: 5.422

10.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Authors:  Thomas A Waldmann; Kevin C Conlon; Donn M Stewart; TatYana A Worthy; John E Janik; Thomas A Fleisher; Paul S Albert; William D Figg; Shawn D Spencer; Mark Raffeld; Jean R Decker; Carolyn K Goldman; Bonita R Bryant; Michael N Petrus; Stephen P Creekmore; John C Morris
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.